Public perception on COVID-19 vaccination intention

Zaid¹, Katon Pratondo²
¹Master of Law, Universitas Muhammadiyah Yogyakarta, Yogyakarta, Indonesia
²Department of Management, Faculty of Economics and Business, Universitas Pembangunan Nasional “Veteran”, Yogyakarta, Indonesia

ABSTRACT

To resolve the health crisis caused by coronavirus disease (COVID-19), the Indonesian government is trying to implement a mandatory vaccination policy for all Indonesians. It was just that the success of this policy is largely determined by acceptance preceded by the public intention to be vaccinated, in which public perception plays a major role in determining intention. This research, therefore, aimed to evaluate and examine the role of perceived risk, benefit, and susceptibility on the COVID-19 vaccination intention. By using a cross-sectional approach, this quantitative study involved 98 participating respondents who were determined by the purposive sampling method. The results of this study finally found and proven that perceived risk (β=0.290 and T-value 2.456 with p-value=0.011), perceived benefits (β=0.394 and T-value 3.873 with p-value=0.000), and perceived susceptibility (β=0.233 and T-value 3.230 with p-value=0.001) had a positive and significant effect on the COVID-19 vaccination intention.

Keyword
COVID-19
Perceived benefit
Perceived risk
Perceived susceptibility
Vaccination intention

Corresponding Author:
Zaid
Master of Law
Universitas Muhammadiyah Yogyakarta
Geblagan, Taman Tirto, Kasihan, Bantul Regency, Special Region of Yogyakarta, Indonesia
Email: zaidrusdianto@gmail.com

1. INTRODUCTION

Since the first time the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared and was first identified in late 2019 in Wuhan, China, it has caused tremendous panic in various countries. Only a few months later, this virus has resulted in a global pandemic known as the COVID-19 pandemic. Since it was first identified in Indonesia, COVID-19 has caused widespread panic throughout Indonesia and has become a significant factor in causing the health crisis to the economy. Several steps have been implemented by the Indonesian Government to deal with and tackle COVID-19. It is starting from large-scale social restrictions (also known as PSBB) regulations, social distancing rules, using masks and face shields in crowds, adopting new normal, but the results were still insignificant [1]. As a result, until the end of 2020, the Government began planning vaccinations for all Indonesians. This was further strengthened until at the beginning of 2021 through Presidential Regulation (Perpres) Number 14 of 2021 on Amendments to Presidential Regulation Number 99 of 2020 on Vaccines Procurement and Implementation of Vaccinations in the Context of COVID-19 Pandemic Prevention, which requires vaccination for all Indonesians who have been designated as the target recipient of the COVID-19 Vaccine as mentioned in Article 13A.

There is no doubt that currently, the burden of the global contagious pandemic is changing. To reduce this, the immunization strategy through vaccination has indeed become the suggestion needed to accommodate this change [2]. The development of vaccines is one of the most fundamental and most significant advances in the history of medicine and public health achievements [3]. Vaccine programs have
played an essential role in preventing significant epidemics of various life-threatening [4]. Vaccines are also a form of right to the highest health standard for the most substantial public health defense against infectious diseases and the most effective way to control diseases caused by pandemics in the modern era [5]–[8]. Especially during the COVID-19 pandemic like today [9]. Therefore, Scientists are racing against time to provide vaccinations proven to be effective [10]. The pace of scientific discovery regarding the COVID-19 vaccine is unprecedented [11].

Currently, developing a vaccine against SARS-CoV-2 and its global access is a priority to end the pandemic. Based on the Decree of the Minister of Health of the Republic of Indonesia Number HK.01.07/MENKES/12758/2020 on the Determination of Types of Vaccines for the Implementation of COVID-19 Vaccination that Indonesia stipulates seven types of vaccines to be used are vaccines produced by PT Bio Farma, Oxford-AstraZeneca, Sinopharm, Moderna, Novavax, Pfizer-BioNTech, and Sinovac. However, the success of this strategy certainly depends on the acceptance of the vaccine by the public. Meanwhile, acceptance depends on the public intention.

Vaccination intention is behavioural intentions described based on the theory of planned behaviour (TPB) introduced in the 1990s [12]. The intention indicates a person's strong readiness to perform a certain behaviour [13]. Thus, vaccination intention is defined as an antecedent of the actual behaviour of the vaccination [14]. In vaccination intentions, one thing that must be eliminated is doubt. So it is important to determine understanding the factors associated with vaccination intentions to overcome doubts about being vaccinated [15]. As declining public confidence in vaccination can persist in many countries, stronger behavioural research and its antecedents need to be undertaken, especially in Indonesia, where less research has been identified [16]. Apart from factors such as knowledge [17], [18], recommendations [19], political ideology [20], framing [21], and information sharing [22] perceptual factors also need to be taken into account. Because strategies that are effective in limiting the spread of disease and optimise vaccination rates during a pandemic cannot be separated from the perceptions that thrive in the community public [8]. Perceived risk is one of the most influential on vaccination intention among many other instruments. The perceived risk referred to in this study is the fear and worry [23] that a person feels about the vulnerability or possible danger (both to himself and the surrounding environment) that will occur if not vaccinated and the perception of the consequences [24], [25]. The large data set from previous studies has shown that apart from rolling, an important role in various medical-related behaviours. Such as perceptions of disease severity, adherence to treatment [26], and vaccination decisions [27], perceived risk is also empirically proven to be closely related and strongly influence vaccination intention [23], [28]–[31].

Besides perceived risk, previous researches have also confirmed in their findings that perceived benefits [31]–[36] and perceived susceptibility [37], [38] could also shape vaccination intention and decision with the predictive power of each determinant varies across each study [39]. In addition, a large number of previous studies had focused on the acceptance and adoption of influenza [15], [40], A/H1N1 [41], HPV [42]–[44], Zika Virus (ZikV) [45], and hepatitis vaccines [46]. However unfortunately, there are still few who discuss the COVID-19 vaccine [47], [48]. Taking this exposure into account, this study aims to examine intention in COVID-19 vaccination and identify factors associated with it, such as perceptions of risk, benefit, and susceptibility among the people of the special region of Yogyakarta. Thus the hypothesis presented in this study is that perceived risk (H1), perceived benefit (H2), and perceived susceptibility (3) has a positive effect on vaccination intention (H3), which is described in the theoretical framework of the study shown in Figure 1.

![Figure 1. Theoretical framework](image-url)
2. RESEARCH METHOD

This study aims to examine the factors that influence COVID-19 vaccination intention theoretically refers to TPB [49]. And from TPB's point of view, perception is a strong predictor of vaccination intention [1]. Therefore, this quantitative research with a cross-sectional approach involved four research constructs consisting of an exogenous construct in the form of perceived risk measured by three measurement items [50], benefit by three measurement items [4], and susceptibility by two measurement items [4] and an exogenous construct in the form of vaccine intention measured by three measurement items [50]. The 11 measurement items developed are then used as an online-based questionnaire to be distributed to respondents via a link form sent through social media platforms. Using the purposive sampling method, each respondent was asked to fill in their personal data to fit the criteria expected in this study before finally answering each questionnaire item. After gaining access to 100 respondents for a period of one month (end of December 2020 to end of January 2021), two were eliminated because they were not in accordance with the criteria, while those received and processed were 98 data samples which were people who is male (57 people/58.16%) and female (41 people/41.84%) with a vulnerable age of 11-19 years as adolescents (33 people/33.67%), 20-60 years old as adults (27 people/27.55%), and >60 years as elderly (38.78%) with employment status as public employees (16 people/16.33%), private employees (27 people/27.55%), self-employees (36 people/36.73%), students (13 people/13.27%) and unemployed (6 people/6.12%), both COVID-19 survivors (39 people/39.80%) and non-survivors (59 people/60.20%) who live in special region of Yogyakarta.

Although the data is relatively small, because this research uses The partial least squares structural equation modeling (PLS-SEM) analysis, the number of sample data can work well [51]. Because it fits the accepted range of sample size requirements[52] and meets the minimum sample size of N ≥ 25 and N ≥ 50+ M (the number of predictors) standards [53] and also the five times rule or five Event per Predictor Parameter (EPP) [54]. The data is then used as the primary source, then analyzed using PLS-SEM with the SmartPLS 3.0 data processing application.

3. RESULTS AND DISCUSSION

In the PLS-SEM analysis method, the first thing to do is assess the model so that the model is a composite or full-structure model. A model is considered a composite structure if it fulfills two assessment models, namely measurement and structural model assessment [55]. The measurement model is implemented to test the reliability and validity of each construct and research item to examine the appropriateness of the relationship between the indicators and construct variables [56]. The reliability test can be carried out and referred to three stages. The first is the stage of seeing the reliability value of each item shown by the loading value. An indicator item can be a reliable level if the construction explains at least more than 50% (0.50) of the loading value of the indicator variant. However, the indicated value should be >0.70 to be claimed as satisfactory reliability [57], [58].

Based on the loading value shown in Table 1, where the overall loading value per item exceeds 70% (>0.70), it can be ascertained that all items have a satisfactory level of reliability, in addition to assessing the reliability of constructs consistency. The constructs can be claimed to be consistently reliable if it meets the composite reliability (CR) criteria with a tolerance value of 0.60 which is still acceptable [55]. However, CR >0.70% [57], [59] is much better as long as it does not exceed 0.95 [57], [60] and also Cronbach's alpha (α) provided that α >0.70 [61]. The results are shown in Table 2 indicate that the CR value of the entire construct shows >0.70 and <0.95. Also, the α value shown is >0.70, so that it can be assured that the whole construct in this study is reliable.

| Table 1. Measurement model |
|-----------------------------|
| Variabel                    | Loading | α    | CR   | AVE  |
| Perceived risk              |         |      |      |      |
| I am at risk of contracting COVID-19 if I am not vaccinated with the COVID-19 vaccine | 0.858   | 0.806 | 0.833 | 0.716 |
| It is very likely that I will get infected COVID-19 if I don't get the COVID-19 vaccine | 0.891   | 0.806 | 0.833 | 0.716 |
| I and the people around me are likely to get COVID-19 if I don't get the COVID-19 vaccine | 0.782   | 0.796 | 0.880 | 0.709 |
| Perceived benefit           |         |      |      |      |
| I believe that Vaccination effectively protects a person from COVID-19 | 0.877   | 0.795 | 0.894 | 0.808 |
| Vaccination is also very important for the protection of the community from COVID-19 | 0.853   | 0.795 | 0.894 | 0.808 |
| By vaccinating myself, I am contributing significantly to the protection of others who cannot be vaccinated | 0.795   | 0.795 | 0.894 | 0.808 |
| Perceived susceptibility    |         |      |      |      |
| There is a possibility that without COVID-19 vaccination, I will get COVID-19 which could have been prevented by vaccination | 0.934   | 0.795 | 0.894 | 0.808 |
| As long as there is COVID-19, vaccination cannot be avoided at all | 0.865   | 0.795 | 0.894 | 0.808 |
| Vaccination intention       |         |      |      |      |
| I plan to vaccinate myself   | 0.863   | 0.889 | 0.932 | 0.820 |
| I want to be vaccinated with the COVID-19 vaccine | 0.926   | 0.889 | 0.932 | 0.820 |
| I am very serious about vaccinating myself | 0.926   | 0.889 | 0.932 | 0.820 |
To the procedure to assess the validity (convergent and discriminant). A construct can be considered to be valid if the average variance extracted (AVE) value in each construct shows >50% (0.50). For the convergent validity criterion and the average value of the extracted variance from latent variables in the PLS-SEM model is more significant or higher than quadratic correlations among other latent variables for discriminant validity [58], [59], [61], [62]. Based on this, taking into account the AVE value shown in Table 1 and also the average latent variable value higher than the quadratic correlation as shown in Table 2, the overall constructs in this study are surely considered valid because they meet the required criteria.

| Table 2. Discriminant validity |
|--------------------------------|
| PR    | PB   | PS   | VI   |
| Perceived risk (PR) | 0.846 | -    | -    | -    |
| Perceived benefit (PB) | 0.796 | 0.842 | -    | -    |
| Perceived susceptibility (PS) | 0.596 | 0.598 | 0.899 | -    |
| Vaccination intention (VI) | 0.743 | 0.765 | 0.642 | 0.905 |

After completing the assessment of the measurement model, the next pace is to assess the structural model. The structural model has been applied as an assessment test to determine the relationship among research constructs [63], [64] by referring to the determination coefficient ($R^2$) and the effect size ($f^2$) values. Assessing on $R^2$ Assessing on $R^2$ aimed to quantify the accuracy of the prediction of the variance model described for the endogenous or dependent latent variable with conditions that are acceptable if $R^2$ > 0.25 with details of moderate (0.50) or strong (0.75) predictive accuracy [56], [65], [66]. Whereas $f^2$ is applied to evaluate the magnitude of the influence of endogenous (independent) variables on exogenous (dependent) with moderate effect criteria if the value is 0.15 if the value shown is higher than 0.35, it means that the influence is substantial if it is lower to 0.02, it is considered to have a weak effect [56], [64], [65].

Based on the proceeds of data processing through SmartPLS 3.0, the $R^2$ value obtained in the endogenous variable of vaccination intention is 0.667, which means that the prediction accuracy for vaccination intention is 66.7% with moderate or medium criteria. As for the $f^2$ value, data processing results also show that the effect of perceived risk on vaccination intention is 0.087 (8.7%), which means it has a relatively small effect. The magnitude of the similar effect also occurred on the effect of perceived susceptibility on vaccination intention with a value of only 0.098 (9.8%). The magnitude of the effect of the perceived benefits on vaccination intention is in the value of 0.159 (15.9%), which means it is still in a moderate level of influence.

The next pace which is also the last step is to test the hypothesis through path coefficient analysis [56]. Based on Tables 3 and Table 4, it appears that all endogenous variables in this study have a positive and significant direct effect on the intention to the COVID-19 vaccine, which will be further explained one by one. The first hypothesis (H1) of this study, which “perceived risk has a positive and significant effect on the COVID-19 vaccination intention”, seems to be accepted and proven. This is indicated by the evidence of the coefficient value $\beta$ = 0.290 and T-value 2.456 with p-value=0.011. The results of proving this hypothesis are in the same direction and support the results of previous studies [28]–[31], [67]. In addition, this result also implies that individuals who claim to be at risk as measured in this study as a concern that when they are not vaccinated will be at risk and are most likely to be affected by COVID-19 both for themselves and their surroundings so that at the end more likely to intend to get COVID-19 vaccine if it is available. Psychology offers a general proposition as a form of intervention to increase vaccination intention. The proposition states that thoughts, feelings, and risk beliefs can motivate someone to get vaccinated [68]. In fact, the effect of perceived risk on vaccination intention has been considered stronger than objective risk [69]. So based on that explanation, it can be deduced that the more perceived risk of the person for COVID-19, the higher the intention is to be vaccinated with the COVID-19 vaccine.

| Table 3. The summary of hypotheses results |
|--------------------------------------------|
| Coefficient ($\beta$) | T-value | Result |
| Perceived risk → Vaccination Intention (H1) | 0.290 | 2.456* | Accepted |
| Perceived benefit → Vaccination Intention (H2) | 0.394 | 3.873* | Accepted |
| Perceived susceptibility → Vaccination Intention (H3) | 0.233 | 3.230* | Accepted |

Note: *Significance at (p=0.01); **Significance at (p=0.05)
Table 4. The summary of relationships assessment

|                        | Direct effect | Indirect effect | Total effect |
|------------------------|---------------|-----------------|--------------|
|                        | β T-value     | β T-value       | β T-value    |
| Perceived risk → Vaccination intention | 0.290 2.456** | - - | 0.290 2.456** |
| Perceived benefit → Vaccination intention | 0.394 3.873* | - - | 0.394 3.873* |
| Perceived susceptibility → Vaccination intention | 0.233 3.230* | - - | 0.233 3.230* |

Note: *Significance at (p=0.01); **Significance at (p=0.05)

Apart from perceived risk, perceived benefit is also convinced to be one of the factors that motivate a person to get vaccinated. Therefore, this research proposes a second hypothesis (H₂) in the form of "perceived benefit has a positive effect on the COVID-19 vaccination intention". With the coefficient value β=0.394 and T-value 3.873 with p-value=0.000, the bootstrapping results on the SmartPLS 3.0 application prove that the proposed H₂ is accepted and confirmed. The direction of the results of this study is certainly in line with previous supported empirical studies [31]–[36]. The consequence of the desire, will, and intention to be vaccinated is that people perceive that the COVID-19 vaccine provides benefits to them. People feel themselves and the people around them will be more protected if they vaccinate themselves. So from this, it can be considered that perceived benefits are a strong predictor of vaccination intention. Summarized Result of Direct and total effect path among the variables tested as shown in Figure 2.

![Figure 2. Summarized result of direct and total effect path among the variables tested](image)

Another thing that is closely related in this study is the argument developed in the Health Belief Model (HBM) theory that perceived susceptibility has a role as an antecedent that cannot be ignored on vaccine intentions [70]. Therefore the third hypothesis (H₃) offered in this study is perceived susceptibility has a positive and significant effect on the COVID-19 vaccination intention. The value of β=0.233 and the T-value of 3.230 with p-value=0.001 is evidence that H₃ is accepted. The result of this study is certainly in line with previous studies [37], [38] as well as the implication that perceived susceptibility is a strong predictor of vaccine intention [71], [72] and even preventive health behaviour [73]. It means that feelings and perceptions of the susceptibility of being vaccinated will cause a strong desire to be vaccinated. And the higher the perception of susceptibility, the stronger the vaccine’s intention. Thus the overall exogenous variables in this study in the form of perceived risk, benefit, and susceptibility are strong predictors of intention because of their positive and significant impact on vaccination intention.

4. CONCLUSION

Overall, this study seeks to prove and at the same time explain how perceptions (risk, benefit, and susceptibility) can affect vaccination intention. The results demonstrate that both perceived risk, benefit, and susceptibility are strong antecedents or predictors in influencing vaccine interest as hypothesized. However, caution in concluding must be considered, given the deficiencies and limitations of this study. It is clear that this study only covers a small sample (98 people) in one area alone (special region of Yogyakarta), so other researchers in the future will need that research with a larger sample and broader coverage. Several other variables may also need to be investigated and the variables in this study to gain additional insight regarding health behaviour in the public community, especially regarding COVID-19 vaccination.
REFERENCES

[1] M. A. S. P. Erawan, Z. Zaid, K. Pratondo, and A. Y. Lestari, “Predicting COVID-19 Vaccination Intention: The Role of Health Belief Model of Muslim Societies in Yogyakarta,” *Al-Sihah Public Heal. Sci. J.*, vol. 13, no. 1, pp. 36–50, Jun. 2021, doi: 10.24252/AL-SIHAH.V13I1.20647.

[2] F. B. Muhib, C. J. Pecenkia, and A. A. Marfin, “Risk-based Vaccines and the Need for Risk-based Subnational Vaccination Strategies for Introduction,” *Clin. Infect. Dis.*, vol. 71, no. Supplement_2, pp. S165–S171, Jul. 2020, doi: 10.1093/cid/ciaa483.

[3] D. Jolley and K. M. Douglas, “The effects of anti-vaccine conspiracy theories on vaccination intentions,” *PLoS One*, vol. 9, no. 2, p. e89177, Feb. 2014, doi: 10.1371/journal.pone.0089177.

[4] M. Vrđelja, V. Učakar, and A. Kraigher, “From mandatory to voluntary vaccination: intention to vaccinate in the case of policy changes,” *Public Health*, vol. 180, pp. 57–63, Mar. 2020, doi: 10.1016/j.puhe.2019.10.026.

[5] E. Jaffe, A. D. Lyerly, and I. T. Goldfarb, “Pregnant women’s perceptions of risks and benefits when considering participation in vaccine trials,” *Vaccine*, vol. 38, no. 44, pp. 6922–6929, Oct. 2020, doi: 10.1016/j.vaccine.2020.08.059.

[6] B. S. Hooker and N. Z. Miller, “Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders,” *SAGE Open Med.*, vol. 8, p. 2053012120923543, Jan. 2020, doi: 10.1177/2053012120923544.

[7] L. O. Gostin, S. A. Karim, and B. Mason Meier, “Facilitating Access to a COVID-19 Vaccine through Global Health Law,” *J. Law, Med. Ethics.*, vol. 48, no. 3, pp. 622–626, Sep. 2020, doi: 10.1111/jlme.12897.

[8] C. A. Gedengil, A. M. Parker, and B. J. Zikmund-Fisher, “Trends in risk perceptions and vaccination intentions: A longitudinal study of the first year of the H1N1 pandemic,” *Am. J. Public Health*, vol. 102, no. 4, pp. 672–679, Apr. 2012, doi: 10.2105/APHIP.2011.300407.

[9] D. Maciorowski, C. Ogaugwu, S. R. Durvasula, R. Durvasula, and A. Kunnamneni, “Therapeutic and Vaccine Options for COVID-19: Status after 6 Months of the Disease Outbreak,” *SLAS Discovery*, p. 2472555220979579, Dec. 15, 2020, doi: 10.1177/2472555220979579.

[10] P. Peretti-Watel et al., “A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation,” *Lancet Infect. Dis.*, vol. 20, no. 7, pp. 769–770, Jul. 2020, doi: 10.1016/S1473-3099(20)30426-6.

[11] J. McAteer, I. Yildirim, and A. Chahroudi, “The VACCINES act: Deciphering vaccine hesitancy in the time of COVID-19,” *Clinical Infections Diseases*, vol. 71, no. 15, pp. 703–705, Jul. 28, 2020, doi: 10.1093/cid/ciaa433.

[12] I. Ajzen, “The theory of planned behavior,” *Organ. Behav. Hum. Decis. Process.*, vol. 50, no. 2, pp. 179–211, 1991, doi: 10.1016/0749-5978(91)90020-T.

[13] J. Bryer, “Black Parents’ Beliefs, Attitudes, and HPV Vaccine Intentions,” *Clin. Nurs. Res.*, vol. 23, no. 4, pp. 369–383, Aug. 2014, doi: 10.1177/1054773813487749.

[14] L. Ou and S. D. Youngstedt, “The Role of Vaccination Interventions to Promote HPV Vaccine Uptake Rates in a College-Aged Population: a Systematic Review,” *J. Cancer Educ.*, 2020, doi: 10.1007/s13187-020-01806-1.

[15] M. P. Nowalk et al., “Influenza Vaccine Intervention After a Medically Attended Acute Respiratory Infection,” *Health Promot. Pract.*, vol. 20, no. 4, pp. 539–552, 2019, doi: 10.1177/1524839918782137.

[16] E. Karafillakis and H. J. Larson, “The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations,” *Vaccine*, vol. 35, no. 37, Elsevier Ltd, pp. 4840–4850, 2017, doi: 10.1016/j.vaccine.2017.07.061.

[17] Z. J. Yang, “Predicting young adults intentions to get the H1N1 vaccine: An integrated model,” *J. Health Commun.*, vol. 20, no. 1, pp. 69–79, 2015, doi: 10.1080/10810730.2014.904203.

[18] T. Nadarzynski, H. Smith, D. Richardson, C. J. Jones, and C. D. Llewellyn, “Human papillomavirus and vaccine-related perceptions among men who have sex with men: A systematic review,” *Sex. Transm. Infect.*, vol. 90, no. 7, pp. 515–523, 2014, doi: 10.1136/stxtrans-2013-051357.

[19] M. Jones and R. Cook, “Intent to receive an HPV vaccine among university men and women and implications for vaccine administration,” *J. Am. Coll. Heal.*, vol. 57, no. 1, pp. 23–32, 2008, doi: 10.3200/JACH.57.1.23-32.

[20] B. Baumgaertner, J. E. Carlisle, and F. Justwan, “The influence of political ideology and trust on willingness to vaccinate,” *PLoS One*, vol. 13, no. 1, p. e0191728, 2018, doi: 10.1371/journal.pone.0191728.

[21] A. E. Leader, J. L. Weiner, B. J. Kelly, R. C. Hornik, and J. N. Cappella, “Effects of information framing on human papillomavirus vaccination,” *J. Women’s Heal.*, vol. 18, no. 2, pp. 225–233, 2009, doi: 10.1089/jwh.2007.0711.

[22] J. Lechuga, G. R. Swain, and L. S. Weinhardt, “Impact of framing on intentions to vaccinate daughters against HPV: A cross-cultural perspective,” *Ann. Behav. Med.*, vol. 42, no. 2, pp. 221–226, 2011, doi: 10.1007/s12160-011-9273-1.

[23] L. C. Karlsson et al., “Fearing the disease or the vaccine: The case of COVID-19,” *Pers. Individ. Dif.*, vol. 172, Apr. 2021, doi: 10.1016/j.paid.2020.110590.

[24] E. Dubé, C. Laberge, M. Guay, P. Bramadat, R. Roy, and J. Bettinger, “Vaccine hesitancy: An overview,” *Hum. Vaccines Immunother.*, vol. 9, no. 8, pp. 1763–1773, 2013, doi: 10.4161/hv.24657.

[25] R. Schmölzle, B. Renner, and H. T. Schupp, “Health Risk Perception and Risk Communication,” *Policy Insights from the Behavioral and Brain Sciences*, vol. 4, no. 2. SAGE Publications Ltd, pp. 163–169, 2017, doi: 10.1177/2372732217720223.

[26] Y. Hanoch, J. J. Rolison, and A. M. Freund, “Does Medical Risk Perception and Risk Taking Challenge with Age?,” *Risk Anal.*, vol. 38, no. 5, pp. 917–928, 2018, doi: 10.1111/risa.12692.

[27] L. Bond and T. Nolan, “Making sense of perceptions of risk of diseases and vaccinations: a qualitative study combining models of health beliefs, decision-making and risk perception,” *BMC Public Health*, vol. 11, no. 1, p. 943, 2011, doi: 10.1186/1471-2458-11-943.

[28] K. J. Petrie, K. Faasuse, and M. G. Thomas, “Public Perceptions and Knowledge of the Ebola Virus, Willingness to ...
Vaccination, and Likely Behavioral Responses to an Outbreak,” *Disaster Med. Public Health Prep.*, vol. 10, no. 4, pp. 674–680, 2016, doi: 10.1017/dmph.2016.67.

[29] K. Faasse and J. Newby, “Public Perceptions of COVID-19 in Australia: Perceived Risk, Knowledge, Health-Protective Behaviors, and Vaccine Intentions,” *Front. Psychol.*, vol. 11, 2020, doi: 10.3389/fpsyg.2020.051004.

[30] J. Zhang, A. E. White, and I. J. Norman, “Seasonal influenza vaccination knowledge, risk perception, health beliefs and vaccination behaviours of nurses,” *Epidemiol. Infect.*, vol. 140, no. 9, pp. 1569–1577, 2012, doi: 10.1017/S0950268811002214.

[31] L. Doornenkamp, L. van Leeuwen, E. van Gorp, H. Voeten, and M. Goeijenbier, “Determinants of Vaccination Uptake in Risk Populations: A Comprehensive Literature Review,” *Vaccines*, vol. 8, no. 3, p. 480, 2020, doi: 10.3390/vaccines8030480.

[32] K. L. Ratnapradipa, R. Norrenberns, J. A. Turner, and A. Kunerth, “Freshman Flu Vaccination Behavior and Intention During a Nonpandemic Season,” *Health Promot. Pract.*, vol. 18, no. 5, pp. 662–671, Sep. 2017, doi: 10.1177/1524839917712731.

[33] L. P. Wong, H. Alias, P. F. Wong, H. Y. Lee, and S. AbuBakar, “The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay,” *Hum. Vaccines Immunothes.*, vol. 16, no. 99, pp. 2204–2214, 2020, doi: 10.1080/21645515.2020.1790279.

[34] L. B. Myers and R. Goodwin, “Determinants of adults’ intention to vaccinate against pandemic swine flu,” *BMC Public Health*, vol. 11, no. 1, p. 11, 2011, doi: 10.1186/1471-2458-11-15.

[35] S. Mehrolia, S. Alagarsamy, and J. S, “Assessing perceptions of COVID-19 self-protective measures: a structural equation modeling (SEM) approach,” *J. Heal. Res.*, vol. ahead-of-print, no. ahead-of-print, 2021, doi: 10.1108/JHR-07-2020-0244.

[36] E. L. Thompson, A. Garg, A. M. Galvin, J. M. Kasting, and C. W. Wheldon, “Correlates of HPV Vaccination Intentions Among Adults Ages 27–45 Years Old in the U.S.,” *J. Community Health*, pp. 1–10, 2021, doi: 10.1007/s10900-021-00968-3.

[37] J. T. F. Lau, Z. Wang, J. H. Kim, M. Lau, C. H. Y. Lai, and P. K. H. Mo, “Acceptability of HPV Vaccines and Associations with Perceptions Related to HPV and HPV Vaccines Among Men Who Have Sex with Men in Hong Kong,” *PLoS One*, vol. 8, no. 2, pp. 1–12, 2013, doi: 10.1371/journal.pone.0057204.

[38] A. Chan, B. Brown, E. Sepulveda, and L. Teran-Clayton, “Evaluation of fotonovela to increase human papillomavirus vaccine knowledge, attitudes, and intentions in a low-income Hispanic community,” *BMC Res. Notes*, vol. 8, no. 1, p. 615, 2015, doi: 10.1186/s13104-015-1609-7.

[39] N. T. Nancy Chen, “Predicting Vaccination Intention and Benefit and Risk Perceptions: The Incorporation of Affect, Trust, and Television Influence in a Dual-Mode Model,” *Risk Anal.*, vol. 35, no. 7, pp. 1268–1280, 2015, doi: 10.1111/risa.12348.

[40] E. P. Armitage et al., “Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia,” *Vaccine*, vol. 36, no. 13, pp. 1772–1780, 2018, doi: 10.1016/j.vaccine.2018.02.037.

[41] M. Sethon and J. Raude, “Factors in vaccination intention against the pandemic influenza A/H1N1,” *Eur. J. Public Health*, vol. 20, no. 5, pp. 490–494, 2010, doi: 10.1093/eurpub/ckq054.

[42] A. L. Krawczyn et al., “Human papillomavirus vaccination intentions and uptake in college women,” *Heal. Psychol.*, vol. 31, no. 5, pp. 685–693, 2012, doi: 10.1093/hep/ckq054.

[43] V. L. Sanders Thompson, L. D. Arnold, and S. R. Notaro, “African American parents’ HPV vaccination intent and concerns,” *J. Health Care Poor Underserved*, vol. 23, no. 1, pp. 290–301, 2012, doi: 10.1353/hpa.2012.0007.

[44] J. Z. Yang and M. M. Pittman, “The Silver Lining of Shame: Framing HPV to Influence Vaccination Intentions,” *Health Commun.*, vol. 32, no. 8, pp. 987–994, 2017, doi: 10.1080/10410236.2016.1196420.

[45] M. Stafford, S. Prabhu, S. A. Egea, M. D. C. G. Gonzalez, and A. K. Shetty, “Knowledge and attitudes about zika virus infection and vaccine intent among medical students in Costa Rica,” *Am. J. Trop. Med. Hyg.*, vol. 103, no. 6, pp. 2453–2459, 2020, doi: 10.4269/ajtmh.19-0748.

[46] C. Liu, S. Nichols, and J. Wang, “The association between protection motivation and hepatitis b vaccination intention among migrant workers in Tianjin, China: A cross-sectional study,” *BMC Public Health*, vol. 20, no. 1, p. 1219, 2020, doi: 10.1186/s12889-020-09292-2.

[47] K. J. Head, M. L. Kasting, L. A. Sturm, J. A. Hartsock, and G. D. Zimet, “A National Survey Assessing SARS-CoV-2 Vaccination Intentions: Implications for Future Public Health Communication Efforts,” *Sci. Commun.*, vol. 42, no. 5, pp. 698–723, 2020, doi: 10.1177/1075547020960463.

[48] Y. Yu, J. T. F. Lau, M. M. C. Lau, M. C. S. Wong, and P. K. S. Chan, “Understanding the Prevalence and Associated Factors of Behavioral Intention of COVID-19 Vaccination Under Specific Scenarios Combining Effectiveness, Safety, and Cost in the Hong Kong Chinese General Population,” *Int. J. Heal. Policy Manag.*, vol. 2021, pp. 1–12, 2021, doi: 10.34172/ijhpm.2021.02.

[49] L. Shmueli, “Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model,” *BMC Public Health*, vol. 21, no. 1, pp. 1–13, Dec. 2021, doi: 10.1186/s12889-021-10816-7.

[50] C. Lagoe and K. M. Farrar, “Are you willing to risk it? The relationship between risk, regret, and vaccination intent,” *Psychol. Heal. Med.*, vol. 20, no. 1, pp. 18–24, 2015, doi: 10.1080/13548506.2014.911923.

[51] D. Iacobucci, “Structural equations modeling: Fit Indices, sample size, and advanced topics,” *J. Consum. Psychol.*, vol. 20, no. 1, pp. 90–98, 2010, doi: 10.1016/j.jcps.2009.09.003.

[52] E. J. Wolf, K. M. Harrington, S. L. Clark, and M. W. Miller, “Sample Size Requirements for Structural Equation Models: An Evaluation of Power, Bias, and Solution Propriety,” *Educ. Psychol. Meas.*, vol. 73, no. 6, pp. 913–934.
Dec. 2013, doi: 10.1177/0013164413495237.

[53] D. G. Jenkins and P. F. Quintana-Ascencio, “A solution to minimum sample size for regressions,” PLoS One, vol. 15, no. 2, pp. 1-15, Feb. 2020, doi: 10.1371/JOURNAL.PONE.0229345.

[54] R. D. Riley et al., “Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes,” Stat. Med., vol. 38, no. 7, pp. 1276–1296, Mar. 2019, doi: 10.1002/SIM.7992.

[55] F. J. J. Hair, W. C. Black, B. J. Babin, and R. E. Anderson, “Multivariate Data Analysis, Eighth Edition,” Hampshire: Cengage Learning EMEA, 2019.

[56] J. F. Hair, M. Sarstedt, L. Hopkins, and V. G. Kuppelwieser, “Partial least squares structural equation modeling (PLS-SEM): An emerging tool in business research,” European Business Review, vol. 26, no. 2. Emerald Group Publishing Ltd., pp. 106–121, Mar. 04, 2014, doi: 10.1108/EBR-10-2013-0128.

[57] M. Sarstedt, C. M. Ringle, and J. F. Hair, “Partial Least Squares Structural Equation Modeling,” in Handbook of Market Research, Cham: Springer International Publishing, 2017, pp. 1–40.

[58] M. Mehmetoglu, “Partial least squares approach to structural equation modeling for tourism research,” Adv. Hosp. Leis., vol. 8, pp. 43–61, 2012, doi: 10.1108/S1745-3542(2012)0000008007.

[59] J. F. Hair, M. Sarstedt, C. M. Ringle, and J. A. Mena, “An assessment of the use of partial least squares structural equation modeling in marketing research,” J. Acad. Mark. Sci., vol. 40, no. 3, pp. 414–433, May 2012, doi: 10.1007/s11457-011-0261-6.

[60] J. F. Hair, G. T. M. Hult, C. Ringle, and M. Sarstedt, “A Primer on Partial Least Squares Structural Equation Modeling (PLS-SEM),” Second edition., Thousand Oaks: Sage, 2017.

[61] J. Riou, H. Guyon, and B. Falissard, “An introduction to the partial least squares approach to structural equation modeling: a method for exploratory psychiatric research,” Int. J. Methods Psychiatr. Res., vol. 25, no. 3, pp. 220–231, 2016, doi: 10.1002/impr.1497.

[62] J. F. Hair, M. C. Howard, and C. Nitzel, “Assessing measurement model quality in PLS-SEM using confirmatory composite analysis,” J. Bus. Res., vol. 109, pp. 101–110, 2020, doi: 10.1016/j.jbusres.2019.11.069.

[63] R. Weston and P. A. Gore, “A Brief Guide to Structural Equation Modeling,” Couns. Psychol., vol. 34, no. 5, pp. 719–751, Sep. 2006, doi: 10.1177/0010000626345.

[64] J. Henseler, G. Hubona, and P. A. Ray, “Using PLS path modeling in new technology research: Updated guidelines,” Ind. Manag. Data Syst., vol. 116, no. 1, pp. 1–20, 2016, doi: 10.1108/IMDS-09-2015-0382.

[65] F. Ali, S. M. Rasoolimanesh, M. Sarstedt, C. M. Ringle, and K. Ryu, “An assessment of the use of partial least squares structural equation modeling (PLS-SEM) in hospitality research,” Int. J. Contemp. Hosp. Manag., vol. 30, no. 1, pp. 514–538, 2018, doi: 10.1108/IJCHM-10-2016-0568.

[66] E. E. Rigdon, C. M. Ringle, and M. Sarstedt, “Structural modeling of heterogeneous data with partial least squares,” Rev. Mark. Res., vol. 7, pp. 255–296, 2010, doi: 10.11584/6435(2010)0000007011.

[67] L. C. Karlsson et al., “Fearing the disease or the vaccine: The case of COVID-19,” Pers. Individ. Dif., vol. 172, p. 110590, 2021, doi: 10.1016/j.paid.2020.110590.

[68] N. T. Brewer, G. B. Chapman, A. J. Rothman, J. Leask, and A. Kempe, “Increasing Vaccination: Putting Psychological Science Into Action,” Psychol. Sci. Public Interes., vol. 18, no. 3, pp. 149–207, 2017, doi: 10.1177/154856341664350.

[69] O. Isler, B. Isler, O. Kopsacheilis, and E. Ferguson, “Limits of the social-benefit motive among high-risk patients: A field experiment on influenza vaccination behaviour,” BMC Public Health, vol. 20, no. 1, p. 240, 2020, doi: 10.1186/s12889-020-02446-3.

[70] M. A. Gerend and J. E. Shepherd, “Predicting human papillomavirus vaccine uptake in young adult women: Comparing the health belief model and theory of planned behavior,” Ann. Behav. Med., vol. 44, no. 2, pp. 171–180, 2012, doi: 10.1007/s12160-012-9366-5.

[71] M. N. Staines, N. M. Rozanti, L. B. Simangunsong, and A. Wahab, “Improvement of Parent’s awareness, knowledge, perception, and acceptability of human papillomavirus vaccination after a structured-educational intervention,” BMC Public Health, vol. 20, no. 1, p. 1836, 2020, doi: 10.1186/s12889-020-09962-1.

[72] A. L. Wagner et al., “Perceptions of measles, pneumonia, and meningitis vaccines among caregivers in Shanghai, China, and the health belief model: A cross-sectional study,” BMC Pediatr., vol. 17, no. 1, p. 143, 2017, doi: 10.1186/s12887-017-0900-2.

[73] C. L. Jones, J. D. Jensen, C. L. Scherr, N. R. Brown, K. Christy, and J. Weaver, “The Health Belief Model as an Explanatory Framework in Communication Research: Exploring Parallel, Serial, and Moderated Mediation,” Health Commun., vol. 30, no. 6, pp. 566–576, 2015, doi: 10.1080/10410236.2013.873363.